News
RVPHW
0.5300
+11.58%
0.0550
Weekly Report: what happened at RVPHW last week (0422-0426)?
Weekly Report · 4h ago
Weekly Report: what happened at RVPHW last week (0415-0419)?
Weekly Report · 04/22 09:43
REVIVA PHARMACEUTICALS HOLDINGS- FDA INDICATED IT WILL REQUIRE A LONG-TERM RANDOMIZED WITHDRAWAL STUDY POST-APPROVAL TO SUPPORT MAINTENANCE OF EFFECT
Reuters · 04/15 12:30
REVIVA PHARMACEUTICALS HOLDINGS, INC. - GAINED ALIGNMENT WITH FDA ON ITS REGISTRATIONAL PHASE 3 PROGRAM FOR BRILAROXAZINE IN SCHIZOPHRENIA
Reuters · 04/15 12:30
REVIVA REPORTS FULL YEAR 2023 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS
Reuters · 04/15 12:05
REVIVA PHARMACEUTICALS: PRINCIPALLY ATTRIBUTES ERRORS TO MATERIAL WEAKNESSES IN INTERNAL CONTROL OVER FINANCIAL REPORTING & CLINICAL TRIAL EXPENSES
Reuters · 04/15 11:53
REVIVA PHARMACEUTICALS HOLDINGS, INC.: INTERIM FINANCIAL STATEMENTS FOR QUARTERLY PERIODS IN FY 2023 SHOULD NO LONGER BE RELIED UPON
Reuters · 04/15 11:53
REVIVA PHARMACEUTICALS: PREVIOUSLY-ISSUED FINANCIAL STATEMENTS FOR FY 2022 HAD UNDERSTATED BY ABOUT $3.9 MLN CERTAIN RESEARCH & DEVELOPMENT EXPENSES
Reuters · 04/15 11:53
Weekly Report: what happened at RVPHW last week (0408-0412)?
Weekly Report · 04/15 09:39
Weekly Report: what happened at RVPHW last week (0401-0405)?
Weekly Report · 04/08 09:42
REVIVA PHARMACEUTICALS HOLDINGS, INC. FILES NON- TIMELY 10-K WITH THE U.S. SEC- SEC FILING
Reuters · 04/02 12:01
REVIVA PHARMACEUTICALS- EXPECTS TO REPORT RELATED MATERIAL WEAKNESS IN ITS INTERNAL CONTROLS OVER FINANCIAL REPORTING & ITS DISCLOSURE CONTROLS
Reuters · 04/02 12:01
Weekly Report: what happened at RVPHW last week (0325-0329)?
Weekly Report · 04/01 09:41
Reviva Pharmaceuticals Holdings, Inc. <RVPH.OQ> expected to post a loss of 35 cents a share - Earnings Preview
Reviva Pharmaceuticals Holdings, Inc. Expected to post a loss of 35 cents a share. The company is expected to show change in quarterly revenue when it reports results on March 28. The average analyst rating on the shares is "buy" and the median 12-month price target is $17.00.
Reuters · 03/26 12:38
Weekly Report: what happened at RVPHW last week (0318-0322)?
Weekly Report · 03/25 09:43
Weekly Report: what happened at RVPHW last week (0311-0315)?
Weekly Report · 03/18 09:42
Weekly Report: what happened at RVPHW last week (0304-0308)?
Weekly Report · 03/11 09:41
Weekly Report: what happened at RVPHW last week (0226-0301)?
Weekly Report · 03/04 09:42
Weekly Report: what happened at RVPHW last week (0219-0223)?
Weekly Report · 02/26 09:46
Weekly Report: what happened at RVPHW last week (0212-0216)?
Weekly Report · 02/19 09:46
More
Webull provides a variety of real-time RVPHW stock news. You can receive the latest news about Reviva Pharmaceutcls Hldgs Inc through multiple platforms. This information may help you make smarter investment decisions.
About RVPHW
Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and seeks to commercialize therapeutics for diseases representing unmet medical needs. The Company’s pipeline focuses on the central nervous system, respiratory and metabolic diseases. Its pipeline includes two drug candidates, RP5063 (brilaroxazine) and RP1208. Its lead drug candidate, brilaroxazine, is in clinical development and is to treat multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), attention-deficit/hyperactivity disorder (ADHD), behavioral and psychotic symptoms of dementia or Alzheimer’s disease (BPSD), and Parkinson’s disease psychosis. Brilaroxazine is also ready for clinical development for two respiratory indications, including pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). Its RP1208 drug candidate is a triple reuptake inhibitor (TRI).